JP2020522514A - マルチバイオティック剤及びその使用方法 - Google Patents

マルチバイオティック剤及びその使用方法 Download PDF

Info

Publication number
JP2020522514A
JP2020522514A JP2019566683A JP2019566683A JP2020522514A JP 2020522514 A JP2020522514 A JP 2020522514A JP 2019566683 A JP2019566683 A JP 2019566683A JP 2019566683 A JP2019566683 A JP 2019566683A JP 2020522514 A JP2020522514 A JP 2020522514A
Authority
JP
Japan
Prior art keywords
acyl
acid
core
alcohol
multibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019566683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522514A5 (enExample
Inventor
ジョン パトリック ジュニア ケイシー，
ジョン パトリック ジュニア ケイシー，
デイビッド ベリー，
デイビッド ベリー，
アルフレド カストロ，
アルフレド カストロ，
スティーブン ジェイ． テイラー，
スティーブン ジェイ． テイラー，
フェルディナンド イー． マッサリ，
フェルディナンド イー． マッサリ，
ジョン プラウドフット，
ジョン プラウドフット，
イライジャ ボガート，
イライジャ ボガート，
ティモシー エフ． ブリッグス，
ティモシー エフ． ブリッグス，
Original Assignee
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド, フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド filed Critical フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Publication of JP2020522514A publication Critical patent/JP2020522514A/ja
Publication of JP2020522514A5 publication Critical patent/JP2020522514A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/24—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
JP2019566683A 2017-06-05 2018-06-05 マルチバイオティック剤及びその使用方法 Pending JP2020522514A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762515409P 2017-06-05 2017-06-05
US62/515,409 2017-06-05
US201862613359P 2018-01-03 2018-01-03
US62/613,359 2018-01-03
US201862632531P 2018-02-20 2018-02-20
US62/632,531 2018-02-20
PCT/US2018/036113 WO2018226732A1 (en) 2017-06-05 2018-06-05 Multibiotic agents and methods of using the same

Publications (2)

Publication Number Publication Date
JP2020522514A true JP2020522514A (ja) 2020-07-30
JP2020522514A5 JP2020522514A5 (enExample) 2021-07-26

Family

ID=64566240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019566683A Pending JP2020522514A (ja) 2017-06-05 2018-06-05 マルチバイオティック剤及びその使用方法

Country Status (13)

Country Link
US (2) US20200101030A1 (enExample)
EP (1) EP3634430B1 (enExample)
JP (1) JP2020522514A (enExample)
KR (1) KR20200011972A (enExample)
CN (1) CN110869024A (enExample)
AU (1) AU2018281327A1 (enExample)
BR (1) BR112019025614A2 (enExample)
CA (1) CA3062067A1 (enExample)
IL (1) IL271025A (enExample)
MX (1) MX2019014539A (enExample)
RU (1) RU2019144960A (enExample)
SG (1) SG11201910198UA (enExample)
WO (1) WO2018226732A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537552A (ja) * 2021-10-19 2024-10-10 山東善維免疫科技有限公司 デンプン－インドールカルボン酸誘導体及びその製造方法並びに使用
JP2024541228A (ja) * 2021-11-12 2024-11-08 アークサーダ・アクチェンゲゼルシャフト ポリオール由来の化合物
JP7906307B2 (ja) 2021-10-19 2026-08-18 山東善維免疫科技有限公司 デンプン－インドールカルボン酸誘導体及びその製造方法並びに使用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021528385A (ja) * 2018-06-05 2021-10-21 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 自己免疫障害を治療するためのアシル化活性剤およびその使用方法
EP3801496A4 (en) 2018-06-05 2022-07-06 Flagship Pioneering Innovations V, Inc. SUBSTANCES AND METHODS OF USE FOR THE TREATMENT OF METABOLIC DISEASES AND NON-ALCOHOL FATTY LIVER
WO2020037009A1 (en) 2018-08-13 2020-02-20 Flagship Pioneering Innovations V, Inc. Conjugates and methods of using the same
ES3069209T3 (en) 2018-11-07 2026-06-04 Univ Minnesota Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction
KR20210100120A (ko) * 2018-12-06 2021-08-13 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 모노메틸 푸마르산염-담체 접합체 및 그 사용 방법
CN113993833B (zh) * 2019-06-12 2024-05-10 凯托利皮克斯治疗有限责任公司 酰基封端的3-羟基羧酸及其盐和酯的生产方法
CN114867811B (zh) * 2019-12-26 2025-10-31 住友化学株式会社 粘合剂组合物
WO2021141959A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
WO2021141963A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
JP7737231B2 (ja) * 2020-03-31 2025-09-10 大阪瓦斯株式会社 ジオール化合物およびその重合体ならびにそれらの製造方法
US10738077B1 (en) * 2020-04-09 2020-08-11 Shaanxi University Of Science And Technology Hydroxytyrosol ursodeoxycholic acid ester with antioxidant activity and a method of preparing the same
KR102718991B1 (ko) 2020-09-25 2024-10-16 씨제이제일제당 (주) 스틸벤계 화합물을 포함하는 항콕시듐증 조성물 및 이의 용도
MY198026A (en) * 2020-11-06 2023-07-26 Stellar Biomolecular Res Gmbh Parenteral nutrition formulation and methods of preparation thereof
WO2022140580A1 (en) * 2020-12-24 2022-06-30 Orn Almarsson Xanthophyll derivatives
CN112979464B (zh) * 2020-12-28 2022-02-11 中国农业科学院农产品加工研究所 白藜芦醇共轭亚油酸酯及其制备方法
EP4274573A4 (en) 2021-01-11 2024-12-11 Pacira Pharmaceuticals, Inc. TREATMENT OF HIP PAIN WITH LIPOSOMAL SUSTAINED-RELEASE ANESTHESIA COMPOSITIONS
EP4308084A4 (en) 2021-03-19 2025-04-23 Pacira Pharmaceuticals, Inc. TREATMENT OF PAIN IN PEDIATRIC PATIENTS BY ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS
CN113045416B (zh) * 2021-03-23 2023-08-18 南京纽邦生物科技有限公司 一种(r)-3-羟基丁酰-(r)-3-羟基丁酯的制备方法
WO2023084531A1 (en) * 2021-11-12 2023-05-19 Celagenex Research (India) Pvt. Ltd. A synergistic composition for activating intracellular secondary messenger(camp) pathway
CN114957004A (zh) * 2022-05-20 2022-08-30 上海远志昌浦生物科技有限公司 一种(r)-3-羟基丁酸-(r)-羟基丁酯及其中间体的合成方法和应用
CN115417865A (zh) * 2022-09-20 2022-12-02 上海予君生物科技发展有限公司 一种依拉地平中间体的制备工艺
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
KR20240123157A (ko) * 2023-02-06 2024-08-13 주식회사 카파바이오사이언스 폴리아민이 결합된 아스코르브산 유도체 및 그 제조방법
EP4692049A1 (en) * 2023-03-30 2026-02-11 Mitsui Chemicals, Inc. Amide compound
WO2025038998A1 (en) * 2023-08-17 2025-02-20 University Of Wyoming Materials and methods for inhibiting, preventing, and dispersing biofilms
FR3153997A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d'au moins l’urolithine B sur une peau sensible
EP4791374A1 (en) * 2023-10-13 2026-08-19 L'oreal Cosmetic use of at least urolithin b or c on a sensitive skin
CN117919232B (zh) * 2023-11-30 2024-10-25 上海市东方医院（同济大学附属东方医院） 吲哚丙酸在治疗肝硬化以及免疫性肝损伤的应用
WO2025264604A1 (en) * 2024-06-17 2025-12-26 The Procter & Gamble Company Skin care composition and method of using the same
CN119530194B (zh) * 2024-12-09 2025-06-17 纽柏抗衰老国际医生集团(广州)有限公司 一种端粒酶及其在抗衰老中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040390A2 (de) * 1997-03-11 1998-09-17 Bayer Aktiengesellschaft Oligosaccharide und deren derivate sowie ein chemo-enzymatisches verfahren zu deren herstellung

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
AU7365900A (en) * 1999-09-08 2001-04-10 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US9248088B2 (en) * 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
US20040265345A1 (en) * 2003-06-30 2004-12-30 Perricone Nicholas V. Treatment of skin damage using acetyl carnitine and lipoic acid
AU2005210299A1 (en) * 2004-02-03 2005-08-18 Nippon Shinyaku Co., Ltd. Prodrug comprising 5-aminosalicylate glycoside
DE102005046237A1 (de) * 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
TW200914437A (en) * 2007-06-20 2009-04-01 Ironwood Pharmaceuticals Inc FAAH inhibitors
US8026285B2 (en) 2007-09-04 2011-09-27 Bezwada Biomedical, Llc Control release of biologically active compounds from multi-armed oligomers
FR2923717B1 (fr) * 2007-11-15 2015-01-16 Caudalie Compositions de derives polyphenoliques stilbeniques et leurs applications pour lutter contre les pathologies et le veillissement des organismes vivants
FR2927801B1 (fr) * 2008-02-22 2010-03-05 Sederma Sa Composition cosmetique hydratante comprenant une combinaison d'homarine et d'erythritol
CA2733551C (en) 2008-08-18 2016-06-07 Bioactor Bvba Arabinoxylans for modulating the barrier function of the intestinal surface
KR102236462B1 (ko) * 2012-03-19 2021-04-08 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
WO2014195872A1 (en) * 2013-06-04 2014-12-11 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
CA2958090A1 (en) 2014-08-13 2016-02-18 The Regents Of The University Of California Biodegradable trehalose glycopolymers
EP3862002A1 (en) * 2015-01-26 2021-08-11 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
JP2016222612A (ja) * 2015-06-01 2016-12-28 昭和電工株式会社 化粧料または皮膚外用剤
CA3003283A1 (en) * 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040390A2 (de) * 1997-03-11 1998-09-17 Bayer Aktiengesellschaft Oligosaccharide und deren derivate sowie ein chemo-enzymatisches verfahren zu deren herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. 19, JPN6022026342, 2009, pages 1939 - 1943, ISSN: 0004977247 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537552A (ja) * 2021-10-19 2024-10-10 山東善維免疫科技有限公司 デンプン－インドールカルボン酸誘導体及びその製造方法並びに使用
JP7906307B2 (ja) 2021-10-19 2026-08-18 山東善維免疫科技有限公司 デンプン－インドールカルボン酸誘導体及びその製造方法並びに使用
JP2024541228A (ja) * 2021-11-12 2024-11-08 アークサーダ・アクチェンゲゼルシャフト ポリオール由来の化合物

Also Published As

Publication number Publication date
EP3634430B1 (en) 2024-08-07
RU2019144960A3 (enExample) 2021-09-30
US20200101030A1 (en) 2020-04-02
IL271025A (en) 2020-01-30
BR112019025614A2 (pt) 2020-06-16
CN110869024A (zh) 2020-03-06
SG11201910198UA (en) 2019-11-28
EP3634430A4 (en) 2021-04-14
KR20200011972A (ko) 2020-02-04
WO2018226732A8 (en) 2019-01-17
US20230293458A1 (en) 2023-09-21
AU2018281327A1 (en) 2019-12-05
RU2019144960A (ru) 2021-07-12
EP3634430A1 (en) 2020-04-15
CA3062067A1 (en) 2018-12-13
WO2018226732A1 (en) 2018-12-13
MX2019014539A (es) 2020-02-10

Similar Documents

Publication Publication Date Title
US20230293458A1 (en) Multibiotic agents and methods of using the same
JP7592140B2 (ja) 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法
JP6174117B2 (ja) 抗炎症活性でコンジュゲートされた増強された抗インフルエンザ剤
US7645748B2 (en) Sterol/stanol phosphorylnitroderivatives and use thereof
US12115178B2 (en) Acylated active agents and methods of their use for the treatment of autoimmune disorders
JP2011525486A (ja) 活動亢進性免疫系を治療するためのシクロリグナンの使用
WO2011153353A1 (en) Tocopherol derivatives and methods of use
EP3801587A1 (en) Acylated catechin polyphenols and methods of their use for the treatment of cancer
JPH10287617A (ja) 新規ジテルペン類及びジテルペン類を有効成分とする抗ウイルス剤
TWI803858B (zh) 化合物及其醫藥用途
CN104974116B (zh) 韧革菌素酰胺类衍生物及其制备方法与应用
CN1337966A (zh) 具有提高的生物利用度的橙皮素前体
WO2014173957A2 (en) Compound
WO2012116577A1 (zh) 绿原酸类似物及其制备方法和应用
KR20190021213A (ko) 폴리카페오일퀴닉산의 아미드 유도체, 그 제조 방법 및 그 용도
KR100979921B1 (ko) 갈색꽃구름 버섯추출물과 이로부터 분리된 락톤계 화합물 및 이를 포함하는 항 비만제 조성물
JP2013043885A (ja) デヒドロアミノ酸含有グリセロール誘導体
CN104974117B (zh) 韧革菌素二级醇酸酯衍生物及其药物组合物和其应用
CN104974118B (zh) 韧革菌素一级醇酸酯衍生物及其药物组合物和其制备方法与应用
JP6173440B2 (ja) 新規美白剤
JP2005041828A (ja) 新規セラミド誘導体とその制がん剤などへの利用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131